1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Arthropathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cunha, FQ; Cunha, TM; Ferreira, SH; Guerrero, AT; Pinto, LG; Verri, WA; Vieira, SM; Zaperlon, AC; Zarpelon, AC | 1 |
| Egido, J; Herrero-Beaumont, G | 1 |
2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Arthropathies
| Article | Year |
|---|---|
The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia.
Topics: Animals; Dihydropyridines; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Imidazoles; Immune System Diseases; Inflammation; Joint Diseases; Leukocyte Disorders; Leukotriene B4; Male; Mice; Mice, Inbred BALB C; Mice, Knockout; Neutrophils; Platelet Activating Factor; Platelet Membrane Glycoproteins; Prostaglandins; Receptors, G-Protein-Coupled; Time Factors; Zymosan | 2013 |
PAF, a potent proinflammatory mediator, looking for its role in the pathogenesis of joint damage.
Topics: Cytokines; Endothelium, Vascular; Extracellular Matrix Proteins; Humans; Joint Diseases; Neutrophils; Platelet Activating Factor; Rheumatic Diseases; Signal Transduction; Synovial Membrane | 1997 |